Gemtesa Alternatives Compared
| Gemtesa (vibegron) | Botox (onabotulinumtoxinA) | Solifenacin |
|
|---|
| Gemtesa (vibegron) | Botox (onabotulinumtoxinA) | Solifenacin |
|
|||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
Prescription only
Prescribed for Overactive Bladder. Gemtesa may also be used for purposes not listed in this medication guide. |
Prescription only
Botox is approved to treat many conditions, such as chronic migraine, involuntary muscle contractions or twitching, excessive sweating, increased saliva, and overactive bladder to name a few. Botox... View more |
Prescription only
Prescribed for Overactive Bladder, Urinary Frequency, Urinary Incontinence, Neurogenic Bladder, Neurogenic Detrusor Overactivity. Solifenacin may also be used for purposes not listed in this medication guide. View more |
Related suggestions Overactive Bladder
|
|||||||||||||||||||||||
| More about Gemtesa (vibegron) | More about Botox (onabotulinumtoxinA) | More about Solifenacin | ||||||||||||||||||||||||
| Ratings & Reviews | ||||||||||||||||||||||||||
|
Gemtesa has an average rating of 7.7 out of 10 from a total of 207 ratings on Drugs.com. 69% of reviewers reported a positive effect, while 12% reported a negative effect. |
Botox has an average rating of 5.7 out of 10 from a total of 481 ratings on Drugs.com. 47% of reviewers reported a positive effect, while 41% reported a negative effect. |
Solifenacin has an average rating of 5.6 out of 10 from a total of 221 ratings on Drugs.com. 39% of reviewers reported a positive effect, while 34% reported a negative effect. |
||||||||||||||||||||||||
| Side Effects Experienced by Users Side effects are reported in Drugs.com user reviews and not clinically verified. | ||||||||||||||||||||||||||
View all Gemtesa side effects |
View all Botox side effects |
View all Solifenacin side effects |
||||||||||||||||||||||||
| Drug Class | ||||||||||||||||||||||||||
| Generic Availability | ||||||||||||||||||||||||||
|
N/A |
Lower cost generic |
|||||||||||||||||||||||||
| Pricing and Coupons * Prices are without insurance | ||||||||||||||||||||||||||
View all Gemtesa prices |
View all Botox prices |
View all Solifenacin prices |
||||||||||||||||||||||||
| Dosage Forms | ||||||||||||||||||||||||||
|
|
|
||||||||||||||||||||||||
| Brand Names | ||||||||||||||||||||||||||
|
N/A |
Other onabotulinumtoxinA brands include: Botox Cosmetic | VESIcare, VESIcare LS | ||||||||||||||||||||||||
| Half Life Drug half-life is the time required for plasma concentration to reduce to half its original value. | ||||||||||||||||||||||||||
|
94 hours |
N/A |
68 hours |
||||||||||||||||||||||||
| CSA Schedule 1 View glossary of CSA terms | ||||||||||||||||||||||||||
|
Not a controlled drug
Is not subject to the Controlled Substances Act. |
Not a controlled drug
Is not subject to the Controlled Substances Act. |
Not a controlled drug
Is not subject to the Controlled Substances Act. |
||||||||||||||||||||||||
| Pregnancy Category | ||||||||||||||||||||||||||
|
Summary unavailable. See the full pregnancy warnings document. |
Category C
Risk cannot be ruled out
See the full pregnancy warnings document. |
Category C
Risk cannot be ruled out
See the full pregnancy warnings document. |
||||||||||||||||||||||||
| Drug Interactions | ||||||||||||||||||||||||||
|
A total of 148 drugs are known to interact with Gemtesa:
|
A total of 120 drugs are known to interact with Botox:
|
A total of 498 drugs are known to interact with Solifenacin:
|
||||||||||||||||||||||||
| Alcohol/Food/Lifestyle Interactions | ||||||||||||||||||||||||||
|
No known alcohol/food interactions. This does not necessarily mean no interactions exist. Always consult your healthcare provider. |
No known alcohol/food interactions. This does not necessarily mean no interactions exist. Always consult your healthcare provider. |
No known alcohol/food interactions. This does not necessarily mean no interactions exist. Always consult your healthcare provider. |
||||||||||||||||||||||||
| Disease Interactions | ||||||||||||||||||||||||||
| First Approval Date | ||||||||||||||||||||||||||
|
December 23, 2020 |
December 09, 1991 |
November 19, 2004 |
||||||||||||||||||||||||
| WADA Class View classifications | ||||||||||||||||||||||||||
|
N/A |
N/A |
N/A |
||||||||||||||||||||||||
| More Information | ||||||||||||||||||||||||||
| Patient Resources | ||||||||||||||||||||||||||
| Professional Resources | ||||||||||||||||||||||||||
| Related Treatment Guide | ||||||||||||||||||||||||||
|
||||||||||||||||||||||||||
1 The Controlled Substances Act (CSA) schedule information displayed applies to substances regulated under federal law. There may be variations in CSA schedules between individual states.
See also:
Further information
Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.